GlassScriptPhysician profile
Danielle E Sparacino
NPI 1629491535
$2,529.85
in general payments reported to CMS, 2019-2025
30 companies · $789 in 2025
The $789 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $174 · 2022: $433 · 2023: $754 · 2024: $380 · 2025: $789.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,923.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,922.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $603.91 | 2021-2025 | |
| Mayne Pharma Commercial LLC | $240.10 | 2022-2025 | |
| Hologic Sales and Service, LLC | $212.41 | 2021-2025 | Aptima, Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Exeltis, USA INC. | $165.07 | 2023-2025 | Slynd |
| Organon LLC | $153.88 | 2021-2025 | Nexplanon |
| Pfizer INC. | $127.45 | 2021-2025 | |
| Myriad Women'S Health, INC. | $98.42 | 2023 | |
| Millicent US INC | $73.95 | 2024-2025 | Intrarosa, Femlyv |
| Bayer Healthcare Pharmaceuticals INC. | $70.52 | 2021-2025 | |
| Shield Therapeutics INC | $66.85 | 2024-2025 | |
| Novo Nordisk INC | $66.58 | 2023-2025 | |
| Biogen, INC. | $64.60 | 2025 | Zurzuvae |
| Sumitomo Pharma America, INC. | $55.12 | 2023-2025 | Myfembree |
| Phathom Pharmaceuticals, INC. | $54.81 | 2025 | Voquezna |
| Axonics, INC. | $52.50 | 2023 | Bulkamid, Axonics |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $44.48 | 2024-2025 | |
| Therapeuticsmd, INC. | $41.47 | 2022 | |
| Boston Scientific Corporation | $39.88 | 2024-2025 | Bulkamid |
| Mylan Pharmaceuticals INC. | $36.51 | 2021-2022 | |
| Astellas Pharma US INC | $35.95 | 2024-2025 | Veozah |
| Merck Sharp & Dohme LLC | $34.98 | 2022 | |
| Dexcom, INC. | $34.32 | 2025 | Dexcom G6 Transmitter |
| Coopersurgical, INC. | $32.62 | 2025 | Paragard T 380a |
| Baxter Healthcare | $20.93 | 2025 | Tisseel |
| Avion Pharmaceuticals | $20.46 | 2023 | Balcoltra |
| Olympus America INC. | $19.96 | 2025 | Olympus |
| Exact Sciences Corporation | $17.91 | 2025 | The Cologuard Plus Collection Kit |
| Molnlycke Health Care US, LLC | $16.06 | 2024 | Avance, Mepilex Border Post-Op Ag |
| Scynexis, INC. | $15.76 | 2022 | |
| Evofem Biosciences, INC. | $12.39 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Sparacino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.